Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

PHASE3CompletedINTERVENTIONAL
Enrollment

317

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2020

Conditions
Axial SpondyloarthritisNonradiographic Axial SpondyloarthritisNr-axSpA
Interventions
BIOLOGICAL

Certolizumab Pegol

"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringe~* Concentration: 200 mg / ml~* Route of Administration: Subcutaneous injection"

OTHER

Placebo

"* Active Substance: Placebo~* Pharmaceutical Form: Prefilled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous injection"

Trial Locations (105)

Unknown

As0006 125, Birmingham

As0006 120, Scottsdale

As0006 115, Tucson

As0006 155, Beverly Hills

As0006 101, Palm Desert

As0006 143, San Francisco

As0006 160, New Haven

As0006 117, Daytona Beach

As0006 116, DeBary

As0006 124, Fort Lauderdale

As0006 133, New Port Richey

As0006 138, Plantation

As0006 134, Tampa

As0006 106, Vero Beach

As0006 148, Atlanta

As0006 137, Idaho Falls

As0006 102, Cumberland

As0006 141, Cumberland

As0006 111, Wheaton

As0006 127, Boston

As0006 147, Worcester

As0006 110, Eagan

As0006 123, Rochester

As0006 103, St Louis

As0006 114, Brooklyn

As0006 118, Charlotte

As0006 149, Oklahoma City

As0006 105, Portland

As0006 108, Duncansville

As0006 144, Philadelphia

As0006 129, Wyomissing

As0006 156, Orangeburg

As0006 107, Salt Lake City

As0006 104, Seattle

As0006 158, Manitowoc

As0006 113, Onalaska

As0006 208, Camperdown

As0006 210, Coffs Harbour

As0006 204, Footscray

As0006 201, Malvern East

As0006 209, Maroochydore

As0006 205, South Hobart

As0006 202, Victoria Park

As0006 302, Plovdiv

As0006 305, Plovdiv

As0006 304, Rousse

As0006 306, Sevlievo

As0006 300, Sofia

As0006 307, Sofia

As0006 309, Sofia

As0006 308, Varna

As0006 152, Edmonton

As0006 150, Victoria

As0006 326, Hlučín

As0006 324, Hustopeče

As0006 327, Olomouc

As0006 320, Ostrava

As0006 322, Pardubice

As0006 323, Prague

As0006 328, Prague

As0006 329, Prague

As0006 330, Prague

As0006 333, Příbor

As0006 332, Rychnov nad Kněžnou

As0006 331, Zlín

As0006 365, Balatonfüred

As0006 362, Budapest

As0006 363, Budapest

As0006 361, Székesfehérvár

As0006 406, Bydgoszcz

As0006 400, Elblag

As0006 401, Krakow

As0006 402, Krakow

As0006 411, Lublin

As0006 403, Poznan

As0006 404, Poznan

As0006 405, Torun

As0006 407, Warsaw

As0006 408, Warsaw

As0006 409, Warsaw

As0006 410, Warsaw

As0006 413, Wroclaw

As0006 414, Wroclaw

As0006 461, Chelyabinsk

As0006 453, Ivanovo

As0006 450, Kazan'

As0006 451, Kazan'

As0006 458, Kemerovo

As0006 455, Moscow

As0006 466, Moscow

As0006 462, Orenburg

As0006 452, Ryazan

As0006 459, Saint Petersburg

As0006 463, Saint Petersburg

As0006 464, Saint Petersburg

As0006 467, Saint Petersburg

As0006 465, Samara

As0006 454, Saratov

As0006 460, Smolensk

As0006 456, Tolyatti

As0006 457, Yaroslavl

As0006 232, Hualien City

As0006 230, Taichung

As0006 233, Taichung

As0006 231, Taipei

All Listed Sponsors
lead

UCB BIOSCIENCES GmbH

INDUSTRY

NCT02552212 - Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS | Biotech Hunter | Biotech Hunter